These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

329 related items for PubMed ID: 8796816

  • 1. The role of the HER-2/neu oncogene in gynecologic cancers.
    Cirisano FD, Karlan BY.
    J Soc Gynecol Investig; 1996; 3(3):99-105. PubMed ID: 8796816
    [Abstract] [Full Text] [Related]

  • 2. The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer.
    Chang JY, Xia W, Shao R, Sorgi F, Hortobagyi GN, Huang L, Hung MC.
    Oncogene; 1997 Feb 06; 14(5):561-8. PubMed ID: 9053854
    [Abstract] [Full Text] [Related]

  • 3. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy.
    Ross JS, Fletcher JA.
    Stem Cells; 1998 Feb 06; 16(6):413-28. PubMed ID: 9831867
    [Abstract] [Full Text] [Related]

  • 4. Tyrosine kinase activation in breast carcinoma with correlation to HER-2/neu gene amplification and receptor overexpression.
    Bhargava R, Naeem R, Marconi S, Luszcz J, Garb J, Gasparini R, Otis CN.
    Hum Pathol; 2001 Dec 06; 32(12):1344-50. PubMed ID: 11774167
    [Abstract] [Full Text] [Related]

  • 5. HER-2/neu signal transduction in human breast and ovarian cancer.
    Reese DM, Slamon DJ.
    Stem Cells; 1997 Dec 06; 15(1):1-8. PubMed ID: 9007217
    [Abstract] [Full Text] [Related]

  • 6. The HER-2/neu oncogene: prognostic factor, predictive factor and target for therapy.
    Ross JS, Fletcher JA.
    Semin Cancer Biol; 1999 Apr 06; 9(2):125-38. PubMed ID: 10202134
    [Abstract] [Full Text] [Related]

  • 7. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma.
    Santin AD, Bellone S, Van Stedum S, Bushen W, Palmieri M, Siegel ER, De Las Casas LE, Roman JJ, Burnett A, Pecorelli S.
    Cancer; 2005 Oct 01; 104(7):1391-7. PubMed ID: 16116605
    [Abstract] [Full Text] [Related]

  • 8. Basic science of HER-2/neu: a review.
    Hung MC, Lau YK.
    Semin Oncol; 1999 Aug 01; 26(4 Suppl 12):51-9. PubMed ID: 10482194
    [Abstract] [Full Text] [Related]

  • 9. Intracellular coexpression of epidermal growth factor receptor, Her-2/neu, and p21ras in human breast cancers: evidence for the existence of distinctive patterns of genetic evolution that are common to tumors from different patients.
    Shackney SE, Pollice AA, Smith CA, Janocko LE, Sweeney L, Brown KA, Singh SG, Gu L, Yakulis R, Lucke JF.
    Clin Cancer Res; 1998 Apr 01; 4(4):913-28. PubMed ID: 9563885
    [Abstract] [Full Text] [Related]

  • 10. Amplification and overexpression of HER-2/neu (c-erbB2) in endometrial cancers: correlation with overall survival.
    Saffari B, Jones LA, el-Naggar A, Felix JC, George J, Press MF.
    Cancer Res; 1995 Dec 01; 55(23):5693-8. PubMed ID: 7585656
    [Abstract] [Full Text] [Related]

  • 11. Growth factor expression in normal peritoneum of patients with gynecologic carcinoma.
    Jennings TS, Dottino PR, Mandeli JP, Segna RA, Kelliher K, Cohen CJ.
    Gynecol Oncol; 1994 Nov 01; 55(2):190-7. PubMed ID: 7959283
    [Abstract] [Full Text] [Related]

  • 12. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A.
    Yu D, Wolf JK, Scanlon M, Price JE, Hung MC.
    Cancer Res; 1993 Feb 15; 53(4):891-8. PubMed ID: 8094034
    [Abstract] [Full Text] [Related]

  • 13. HER-2/neu (c-erb-B2) gene and protein in breast cancer.
    Ross JS, Fletcher JA.
    Am J Clin Pathol; 1999 Jul 15; 112(1 Suppl 1):S53-67. PubMed ID: 10396301
    [Abstract] [Full Text] [Related]

  • 14. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells.
    Pietras RJ, Fendly BM, Chazin VR, Pegram MD, Howell SB, Slamon DJ.
    Oncogene; 1994 Jul 15; 9(7):1829-38. PubMed ID: 7911565
    [Abstract] [Full Text] [Related]

  • 15. Breast cancer in the 21st century: neu opportunities and neu challenges.
    Schnitt SJ.
    Mod Pathol; 2001 Mar 15; 14(3):213-8. PubMed ID: 11266529
    [Abstract] [Full Text] [Related]

  • 16. Proteomics of breast cancer: enhanced expression of cytokeratin19 in human epidermal growth factor receptor type 2 positive breast tumors.
    Zhang DH, Tai LK, Wong LL, Sethi SK, Koay ES.
    Proteomics; 2005 May 15; 5(7):1797-805. PubMed ID: 15825149
    [Abstract] [Full Text] [Related]

  • 17. A genomic explanation connecting "Mediterranean diet", olive oil and cancer: oleic acid, the main monounsaturated fatty acid of olive oil, induces formation of inhibitory "PEA3 transcription factor-PEA3 DNA binding site" complexes at the Her-2/neu (erbB-2) oncogene promoter in breast, ovarian and stomach cancer cells.
    Menendez JA, Papadimitropoulou A, Vellon L, Lupu R.
    Eur J Cancer; 2006 Oct 15; 42(15):2425-32. PubMed ID: 16406575
    [Abstract] [Full Text] [Related]

  • 18. Liposome-mediated in vivo E1A gene transfer suppressed dissemination of ovarian cancer cells that overexpress HER-2/neu.
    Yu D, Matin A, Xia W, Sorgi F, Huang L, Hung MC.
    Oncogene; 1995 Oct 05; 11(7):1383-8. PubMed ID: 7478560
    [Abstract] [Full Text] [Related]

  • 19. HER-2/neu-targeting cancer therapy via adenovirus-mediated E1A delivery in an animal model.
    Zhang Y, Yu D, Xia W, Hung MC.
    Oncogene; 1995 May 18; 10(10):1947-54. PubMed ID: 7761095
    [Abstract] [Full Text] [Related]

  • 20. Immunohistochemical study of HER-2/neu, epidermal growth factor receptor, and steroid receptor expression in normal and malignant endometrium.
    Bigsby RM, Li AX, Bomalaski J, Stehman FB, Look KY, Sutton GP.
    Obstet Gynecol; 1992 Jan 18; 79(1):95-100. PubMed ID: 1345772
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.